Mirfine 25/50mg – Barter & Marcin Pharma

Mirfine 25/50 mg

Composition

Mirfine 25/50 mg

Monotherapy

Indicated for overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
25 mg PO qDay
25 mg dose is typically effective within 8 weeks
May increase to 50 mg PO qDay based on individual efficacy and tolerability.

Combination With Muscarinic Antagonist

Indicated in combination with the muscarinic antagonist solifenacin succinate for treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Combination regimen: 25 mg PO qDay plus solifenacin succinate 5 mg PO qDay.
May increase mirabegron to 50 mg PO qDay after 4-8 weeks based on individual efficacy and tolerability.

Dosage Modifications

Renal Impairment

Mild-to-moderate (eGFR ≥30 mL/min/1.73 m2): No dosage adjustment required.
Severe (eGFR 15-29 mL/min/1.73 m2): Not to exceed 25 mg/day
eGFR <15mL/min/1.73 m2 or on dialysis: Not recommended.

Hepatic Impairment

Mild (Child-Pugh A): No dosage adjustment required.
Moderate (Child-Pugh B): Not to exceed 25 mg/day for either starting or maximum dose.
Severe (Child Pugh C): Not recommended.

Dosing Considerations

Granules and tablets are 2 different products and are not substitutable on a milligram-per-milligram basis.
Recommended dosage for granules in adults has not been determined.

Leading with integrity, delivering with impact — healthcare that moves lives forward.

SCO 215, 1st & 2nd Floor, Motor Market

Manimajra, Chandigarh, 160101

+91.172.4007092

md@barterandmarcinpharma.com

Copyright © Barter & Marcin Pharma. All Rights Reserved